GlassScriptPhysician profile
Jingdong Su
NPI 1669607479
$11,486.14
in general payments reported to CMS, 2019-2025
64 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,522 · 2020: $263 · 2021: $80.63 · 2022: $469 · 2023: $2,100 · 2024: $2,901 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,964 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,964.22 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,635.79 | 2019-2025 | Imfinzi, Imjudo, Tagrisso |
| Janssen Biotech, INC. | $870.19 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Abbvie INC. | $623.65 | 2019-2025 | |
| Tempus Ai, INC | $555.35 | 2024-2025 | Xt Cdx |
| Amgen INC. | $548.65 | 2019-2024 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $454.29 | 2019-2025 | Opdivo |
| Glaxosmithkline, LLC. | $413.25 | 2023-2025 | Zejula, Ojjaara, Jemperli |
| Incyte Corporation | $341.57 | 2021-2025 | Monjuvi, Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $293.40 | 2019-2025 | Iclusig |
| Genzyme Corporation | $243.09 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $231.54 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $216.65 | 2022-2025 | Libtayo, Lynozyfic |
| Stemline Therapeutics INC. | $196.73 | 2023-2024 | Orserdu, Elzonris |
| Genmab U.S., INC. | $191.46 | 2023-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $190.33 | 2023-2025 | Xpovio |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $188.10 | 2019-2023 | Lunsumio, Polivy |
| Emd Serono, INC. | $186.24 | 2023-2025 | Bavencio |
| Pfizer INC. | $172.94 | 2022-2025 | |
| Exelixis INC. | $167.54 | 2019-2025 | Cabometyx |
| Sobi, INC | $150.05 | 2024 | |
| Lilly USA, LLC | $146.63 | 2019-2025 | Retevmo, Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $145.57 | 2025 | Besremi |
| Galvanize Therapeutics, INC | $144.41 | 2025 | Aliya System |
| Merck Sharp & Dohme LLC | $140.02 | 2019-2025 | Keytruda, Keytruda Qlex |
| Gilead Sciences, INC. | $137.65 | 2019-2022 | |
| Beigene USA, INC. | $133.22 | 2023-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $125.31 | 2019-2024 | Onivyde |
| Clovis Oncology, INC. | $125.00 | 2019 | |
| Astellas Pharma US INC | $124.45 | 2023-2025 | Padcev, Xtandi |
| Syndax Pharmaceuticals, INC. | $124.14 | 2025 | Revuforj |
| Beone Medicines USA, INC. | $124.14 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $123.64 | 2024-2025 | |
| Celgene Corporation | $121.28 | 2023-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $121.25 | 2024-2025 | Enhertu, Vanflyta |
| Jazz Pharmaceuticals INC. | $121.15 | 2019-2024 | |
| Puma Biotechnology, INC. | $121.00 | 2019 | |
| Mirati Therapeutics, INC. | $113.82 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $112.13 | 2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $111.64 | 2021-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $107.34 | 2019 | |
| Pharmacosmos Therapeutics INC. | $101.78 | 2024 | Monoferric |
| Taiho Oncology, INC. | $92.85 | 2023 | |
| Myriad Genetic Laboratories, INC. | $90.60 | 2023 | Myrisk |
| Seagen INC. | $86.74 | 2023 | Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $69.51 | 2024-2025 | |
| Array Biopharma INC | $68.26 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Geron Corporation | $63.52 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $55.60 | 2022-2024 | Ayvakit |
| Tesaro, INC. | $55.04 | 2019 | |
| Iovance Biotherapeutics, INC. | $51.50 | 2024-2025 | Amtagvi |
| Novo Nordisk INC | $46.30 | 2025 | |
| Kite Pharma, INC. | $45.17 | 2021-2025 | Yescarta |
| Morphosys, US INC. | $41.98 | 2022-2023 | Monjuvi |
| Novocure INC. | $32.05 | 2022-2025 | Optune Lua (Novottf-200t) |
| Aveo Pharmaceuticals, INC. | $27.68 | 2024 | |
| Sun Pharmaceutical Industries INC. | $24.12 | 2023 | Odomzo, Yonsa |
| G1 Therapeutics, INC. | $23.75 | 2023 | Cosela |
| Helsinn Therapeutics (U.S.), INC. | $22.27 | 2025 | Akynzeo |
| Shire North American Group INC | $19.10 | 2019 | |
| Acrotech Biopharma INC. | $17.17 | 2025 | Beleodaq |
| Sumitomo Pharma America, INC. | $16.73 | 2023 | Orgovyx |
| Emmaus Medical, INC. | $13.87 | 2023 | Endari |
| Janssen Pharmaceuticals, INC | $13.60 | 2022 | |
| Fortovia Therapeutics, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jingdong Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.